Becker's Healthcare December 20, 2024
Medicaid could spend $29.9 billion on drugs to treat type 2 diabetes and weight loss, according to a report from HHS’ Office of Inspector General.
The report, published Dec. 19, reviewed Medicaid program spending for 10 GLP-1 and SGLT-2 drugs to treat type 2 diabetes between 2019 and 2023. The report also tracked Medicaid spending for Wegovy and Saxenda, two GLP-1 drugs approved for weight loss.
GLP-1 drugs, including Ozempic, Monjauro and Rybelsus, treat type 2 diabetes. The drugs can cost more than $1,000 a month SGLT-2 drugs include Jardiance, Farxiga and Invokana.
Here are five numbers to know from the report:
- Between 2019 and 2023, Medicaid spending on 12 diabetes and...
Today's Sponsors
Today's Sponsor